Core Viewpoint - The announcement by Four Seasons Pharmaceutical (00460) regarding the inclusion of its innovative drug Pirlosil (brand name: XuanYueNing) in the 2025 National Basic Medical Insurance Directory is expected to enhance the drug's affordability and accessibility for patients, positively impacting its market promotion and sales growth [1] Group 1 - Four Seasons Pharmaceutical's subsidiary, XuanZhu Biotechnology, has developed the innovative drug Pirlosil, which will be included in the 2025 National Basic Medical Insurance Directory [1] - The 2025 National Basic Medical Insurance Directory will officially take effect on January 1, 2026 [1] - The inclusion in the insurance directory is anticipated to facilitate the market expansion of Pirlosil, thereby benefiting the long-term operational development of XuanZhu Biotechnology [1] Group 2 - XuanZhu Biotechnology plans to actively cooperate in implementing the insurance policy and will continue to work on hospital access and expanding market coverage [1] - The goal is to enhance patient access to the medication continuously [1]
四环医药：创新药轩悦宁 首次纳入国家基本医保药品目录